Displaying drugs 326 - 350 of 7378 in total
Alprazolam
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse...
Approved
Illicit
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strong) …
Ruxolitinib
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index …
Flutamide
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Gilteritinib
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Heparin
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor...
Approved
Investigational
Matched Products: … Hep-Lock U/P …
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Tazobactam
Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved...
Approved
Matched Mixtures name: … AUROTAZ-P 4.5 G ... Aurotaz-P Powder for Injections 4.5 g …
Methsuximide
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) …
Vandetanib
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Benzyl alcohol
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP2E1 Substrates …
Ziprasidone
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Trazodone
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Categories: … P-glycoprotein inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Bimatoprost
Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Febuxostat
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Substrates …
Mirvetuximab soravtansine
Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRĪ±), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Categories: … P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Ipecac
Ipecac is obtained from the plant Cephaelis ipecacuanha and contains a number of emetic alkaloids including emetine and cephaeline. Ipecac was approved by Health Canada as an OTC but all those products are now discontinued. The FDA does not have currently any approved product containing ipecac, however, ipecac as an...
Approved
Withdrawn
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Maralixibat
Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (weak) …
Nisoldipine
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Ergotamine
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Inhibitors …
Bromocriptine
Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as the treatment of acromegaly. Bromocriptine has been...
Approved
Investigational
Withdrawn
Matched Categories: … P-glycoprotein inhibitors ... P-glycoprotein substrates ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates …
Zopiclone
Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Niacin
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Approved
Investigational
Nutraceutical
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Valdecoxib
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Almotriptan
Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Displaying drugs 326 - 350 of 7378 in total